Bempedoic Acid Dosage

Medically reviewed by Drugs.com. Last updated on Mar 18, 2024.

Usual Adult Dose for Heterozygous Familial Hypercholesterolemia

180 mg orally once a day

Comments:

• This drug should be given with maximally tolerated statin therapy.
• Lipid levels should be checked within 8 to 12 weeks of treatment initiation.

Uses: As an adjunct to diet and maximally tolerated statin therapy for the treatment of heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease in those requiring additional LDL-C lowering.

Usual Adult Dose for Cardiovascular Risk Reduction

180 mg orally once a day

Comments:

• This drug should be given with maximally tolerated statin therapy.
• Lipid levels should be checked within 8 to 12 weeks of treatment initiation.

Uses: As an adjunct to diet and maximally tolerated statin therapy for the treatment of heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease in those requiring additional LDL-C lowering.

Renal Dose Adjustments

Mild to moderate renal impairment (eGFR 30 mL/min/1.73 m2 or greater): No adjustment recommended
Severe renal impairment (eGFR less than 30 mL/min/1.73 m2): Use caution as there is limited experience

Liver Dose Adjustments

Mild to moderate hepatic impairment (Child Pugh A or B): No adjustment recommended
Severe hepatic impairment: Data not available

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Take orally once a day with or without food

General:

• This drug, in combination with maximally tolerated statins (with or without other lipid modifying agents) decreases LDL-C, non-high-density lipoprotein cholesterol, apolipoprotein B, and total cholesterol.
• Concomitant use with simvastatin or pravastatin my increase the risk of simvastatin or pravastatin associated myopathy as it may increase the serum concentrations of these drugs.

Monitoring:

• Lipid levels should be checked within 8 to 12 weeks of therapy initiation
• Serum uric acid levels should be obtained as clinically indicated

Patient advice:

• Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
• Patients should be instructed to report tendinitis or tendon rupture symptoms.
• Patients should be instructed to report signs or symptoms of hyperuricemia.
• Patients should be instructed to speak with their healthcare provider if they are or are planning to become pregnant or breastfeeding.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer